1 recruiting, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Terminated 1 |
Follow Relapsed or Refractory Acute Myeloid Leukemia: new trials by email Literature Review of Relapsed or Refractory Acute Myeloid Leukemia trials Research Report on Relapsed or Refractory Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia Selinexor, Homoharringtonine, Daunorubicin - Relapsed or Refractory Acute Myeloid Leukemia | Phase 3 | Recruiting | Shanxi Bethune Hospital | 50 | 2023-01-29 | 2024-10-22 |
| Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia Dexamethasone, Amsacrine, Cytarabine - Relapsed or Refractory Acute Myeloid Leukemia | Phase 3 | Terminated | University Hospital, Toulouse | 73 | 2020-01-13 | 2025-04-10 |
Leukemia, Myeloid, Acute (2) · Recurrence (2)
Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Leukemia, Myeloid (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Cytarabine (2) · Amsacrine (1) · Azacitidine (1) · Daunorubicin (1) · Dexamethasone (1) · Granulocyte Colony-Stimulating Factor (1) · Homoharringtonine (1) · aclacinomycins (1) · selinexor (1)
Shanxi Bethune Hospital (1) · University Hospital, Toulouse (1)
China (1) · France (1)
Tao Wang (1)